Genexol-PM is a polymeric micelle formulated paclitaxel, free of Cremophor EL. Objectives with Genexol-PM are to reduce Cremophor EL-related toxicities and to increase therapeutic efficacy. Polymeric micelles are composed of hundreds of amphiphilic diblock copolymers. Block copolymers include poly-(ethylene glycol) used as nonimmunogenic carriers and biodegradable core-forming poly-(D,L-lactic acid) to solubilize hydrophobic drug. Genexol-PM showed 3-times higher maximum tolerated dose in mice vs. Taxol. Genexol-PM (vs. Taxol) showed 2-3-fold higher levels of paclitaxel in tissues including liver, spleen, kidney, lung, and tumors. In vivo antitumor efficacy of Genexol-PM was significantly higher than Taxol. Based on results from Phase I and II trials in Korea/US, the therapeutic dose recommended is 300mg/m2, much higher than Taxol (175 mg/m2). With favorable results from Phase II studies - Breast/Lung Cancer, Genexol-PM obtained a pre-market approval in Korea in July 2006. A phase IIa pancreatic cancer trial is on-going in US.